QUORUMCALL//GPT:
BIG PICTURE
– Senator Elizabeth Warren is raising concerns over Novo Holdings’ proposed $165 billion acquisition of Catalent, a contract development and manufacturing organization (CDMO) that is a key player in the COVID-19 vaccine supply chain.
DETAILS
– Warren is questioning the potential antitrust implications of the deal, citing potential risks to the U.S. drug supply chain, especially in the midst of the ongoing pandemic.
– The senator has sent a letter to the Federal Trade Commission (FTC) urging it to scrutinize the acquisition, arguing that the deal could create a “pharmaceutical monopoly” and pose risks to drug affordability and accessibility.
IMPACT
– If the FTC were to take action based on Warren’s concerns, it could potentially put a halt to the deal, which is slated to be one of the largest acquisitions in the pharmaceutical industry.
TOPICS COVERED
– #Antitrust, #Pharmaceuticals, #COVID19, #VaccineSupplyChain
NOTE
– The source publication, Fierce Pharma, is a trade publication specializing in the business and regulatory aspects of the pharmaceutical industry. It is known for its coverage of drug development, manufacturing, and distribution.